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Abstract
Several studies have shown how cytostatics may cause hypofunction of salivary glands but failed to elucidate any 
potentially related side effects. Keeping in mind the sialochemical assistance and the role of saliva on the homeos-
tasis of the stomatognathic system, the aim of this study was to establish potential gland disorders in patients sub-
mitted to 5- Fluorouracil (5-Fu) and  Leucovorin calcium(LV) as well as their correlation with certain oral health 
disorders that diminish the quality of life.
Materials and methods: the focus of this research was observational and longitudinal. Twenty-five patients diag-
nosed with colon cancer at an initial, intermediate and late phase submitted to specifically devised therapy were 
assessed. Clinical history, oral health indexes and basal or stimulated saliva samples were recorded.
Results: Basal and stimulated flow dropped in the intermediate stage. Stimulated saliva pH decreased during 
treatment.  On basal saliva, urea, sodium and potassium rose during the intermediate phase. Löe and Silness rates 
as well as simplified bleeding increased during therapy but reverted by the end of the treatment. Depth index of 
the vestibular gingival sulcus rose during the intermediate phase but did not return.
Conclusion: This treatment caused functional salivary gland disorders as evidenced by basal and stimulated hypo-
sialia, and acidification of stimulated saliva pH during the intermediate phase.  Increase in basal urea may be due 
to proteic catabolism arising from plasma or glands. Variation in Na+ and K+ of basal saliva concentrates might 
be assumed as a possible duct disorder. Recovery of bleeding and Löe and Silness rates may point to a transient 
inflammatory effect associated to a decrease in salivary flow. Increase in the depth rates of   the periodontal ves-
tibular sulcus could be correlated with a higher risk of periodontal disease.
Key words: 5- Fluorouracil + Leucovorin Calcium, salivary glands, dysfunction, xerostomia, oral health in-
dexes. 
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Introduction
Numerous side effects in the oral cavity are caused by 
chemotherapy, which should be minimized to relieve 
discomfort and maintain its healthy performance.
It is hard to reach definite conclusions about the influen-
ce of chemotherapy over salivary gland activity due 
to the limited or lack of suitable methods of recording 
small samples, short time of assays, and variety of ma-
nagement for different types of cancer.
Among the various therapeutical schemes, 5-Fluoruracil 
(5-Fu) and Leucovorin Calcium (LV), are two widely used 
drugs for the treatment of colon and rectum cancer (1-5). 
5-Fu is classified as an analogue of pyrimidine bases that 
adds a fluor atom in position 5, replacing a hydrogen and 
damaging malignant cells two ways: by inhibiting thy-
midylate synthetase and by RNA bonding.
On the other hand, Leucovorin calcium, acts as a mo-
dulator of 5-Fu amplifying its range  of action.  Conco-
mitant use of both drugs enhances the therapeutical and 
toxic effects of 5-Fu  (6). An alternative in the adminis-
tration of these cytostatics is the ambulatory manage-
ment, with six  I.V. cycles  during five consecutive days 
and a twenty-five day intermission. 
The administration of these drugs is designed keeping 
in mind the body surface of the patient. This way, phar-
macological induction of 5- Fu and LV can be extended 
for approximately six months.
This treatment exerts deleterious effects on several or-
ganic systems. Within the oral cavity, it initiates mor-
phologic, structural and ultra structural disorders that 
promote dysfunctions, namely, salivary gland hypo-
function (7,8). 
Several authors claim these drugs would directly affect 
glands and thereby the product of their secretion, while 
others suggest that saliva would become the vehicle of 
such drugs inside the oral cavity, thus causing cytotoxi-
city (9).
Clinical assessment may elicit a subjective response 
from the patient such as dry mouth sensation or xeros-
tomia or objective findings like flow and sialochemical 
assays. Dry mouth sensation does not necessarily agree 
with objective evaluations (10).
Based on these records and keeping in mind the rele-
vant role of this complex exocrine secretion vital to the 
homeostatic balance of the stomatognathic system (11), 
the aim of the present work was to assess within a thera-
peutical frame work, the possible alterations in human 
saliva  and their impact on oral health of colon cancer 
patients during the different  stages of their treatment.
Material and Methods
The observational and longitudinal study was perfor-
med on twenty –five patients from the Oncology Unit of 
Sanatorio Allende, Cordoba, Argentina diagnosed with 
colon cancer and submitted to 5-Fu and LV treatment 
during six cycles of five consecutive days with a twenty 
–one day intermission between them.
Patients were assessed based on the following scheme:
1- Initial phase: Prior to treatment.
2- Intermediate phase: Prior to the fourth drug admi-
nistration.
3- Late phase: Twenty-one days after the end of the 
treatment.
Patients of both sexes between 21 and 75 years of age 
with colon cancer diagnosis and no previous stomatologic 
complaints were included in this survey. Patients exposed 
to neck and head radiation suffering from metabolic and 
mental disorders were not included in this survey.
Clinical management warranted risk free procedures or 
any discomfort inflicted on the patients, complying with 
anonymity, and confidentiality policies.
Once the written consent was granted and signed ac-
cording to the standard model approved by the ethical 
committee of Sanatorio Allende, a clinical history was 
made. Oral exam of the mouth and samples of basal and 
stimulated saliva were collected in the morning so as 
not to disturb the circadian rhythm of secretion (12-14). 
The following oral health parameters were assessed for 
each patient:
a- odontogram
b- Löe and Silness rates (14,15)
c- simplified bleeding indexes (16)
d- Ramfjord  index (17)
e- plaque index (18).
f- Probing depth of the vestibular sulcus of the elements 
13-23-33 and 43  plus 16-26-36 and 46.
Collection of stimulated and basal saliva was carried 
out for five minutes using a 1 square cm inert rubber 
piece (19,20). Samples were maintained at –40C for fur-
ther assay. The following assays were made:
a- Salivary flow and pH.
b- Organic components: whole proteins, salivary amyla-
se, Ig A  and urea.
c- Inorganic components: ionogram in saliva (Na+, K+, 
Cl-), Ca++, PO4=.-
Statistical Analysis: data were analyzed by Student “T” 
test for paired data to compare the different stages of 
treatment, setting a P value< 0.05 for statistical signi-
ficance.
Results
Mean age of the patients with colon cancer was 55 years 
old, with 43% and 57% of subjects respectively younger 
or older than the mean.  Regarding genetic predisposi-
tion, only 36% reported cancer history (only first and 
second degree line ancestors were taken into account). 
Both basal and stimulated flow dropped significantly in 
the intermediate stage as compared with the initial pha-
se but reverted 21 days after treatment had ended. (p> 
0.05 and p> 0.01 respectively). (Fig.1).  As regards pH, 
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Fig. 2. Effect of 5 – FU and LV over basal and stimulated saliva pH of patients at different treatment 
phases. :  basal flow; :stimulated flow. (*): p< 0.05: intermediate, stimulated flow versus initial and 
final.
Fig. 1. Effect of 5 – FU and LV over basal and stimulated saliva flow from  patients at diferent 
treatment phases: basal flow; : stimulated flow. (*): p< 0.05:  intermediate basal flow versus initial 
and final; (**): p< 0.01 intermediate stimulated flow versus initial and final.
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basal saliva showed no statistically significant changes, 
but stimulated saliva acidified in the intermediate as 
compared with the initial phase. This effect reverted 
during the final stage, when mechanical stimulation 
promoted saliva secretion with a pH similar to that of 
the initial stage (p< 0.05) (Fig.2).
As for basal saliva composition, inorganic components 
such as Na+ and K+ increased during the intermediate 
unlike the initial stage but recovered in the final phase.
 Among organic components, only a significant increase 
in urea concentration was evidenced during cytostatics 
administration that reverted in the late stage. (Table 1)
Oral health indexes yielded the following results:
Gingival inflammatory response, evaluated by Löe and 
Silness rates, increased in the intermediate unlike the 
initial stage (p< 0.0001), and reverted by the end of the 
treatment (Fig.3a). The simplified bleeding index exhi-
bited a rise over the periodontal probing in the interme-
diate as compared with the initial phase (p< 0.0001). 
Such an effect was reverted in the late stage (Fig.3b).
Depth index of the vestibular sulcus of anterior and pos-
terior elements significantly increased in the interme-
diate phase but did not revert at the end of the treatment 
(p <0.0001) (Fig.3c). Odontogram, plaque and Ramfjord 
indexes revealed no significant differences in the stu-
died sample.
Conclusions
It is well known that many cytostatic drugs disturb the 
health status of the stomatognathic system but their real 
impact on gland tissue is not fully elucidated.
The current paper ratified the deleterious effect of the-
se drugs discarding certain issues that  complicate data 
analysis such as interpersonal variations since every 
individual in the survey was evaluated during the di-
fferent stages of the therapy. The schedule of treatment 
applied mainly caused stimulated salivary glands disor-
ders   and basal hyposalivation. This might be the cau-
se of xerostomia or dry mouth sensation with burning, 
dorsal lingual distress, lips and corners of the mouth 
cracking, discomfort in the use of  removable dentu-
res,  and impaired swallowing and chewing in addition 
to dysgeusia (21). Basal and stimulated saliva pH was 
affected differently. Even though basal saliva pH expe-
rienced no changes, stimulated saliva pH acidified in 
the intermediate stage. This finding, along with a drop 
in the amount of flow released, would modify healthy 
flora (22-24). 
Many physiologic processes involved in electrolyte 
exchange are susceptible to chemotherapy effects. As 
regards inorganic substances, increase in Na+ and K+, 
would suggest a disorder in duct transport mechanisms 
during ions re- arrangement which occurs during se-
condary saliva formation.
Urea, which rose in the intermediate stage was the only 
Fig. 3. Effect of 5 – FU and LV over Löe and Silness index, bleeding index 
and depth of gingival sulcus index of patients at different treatment phas-
es. (***): p< 0.0001: intermediate versus initial and final (a and b); initial 
phase anterior and posterior areas, versus intermediate and final (c).
a
b
c
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organic component that exhibited significant difference.
This change may be a catabolic protein effect arising 
either from blood  plasma or from the gland itself. Re-
sults related to whole protein concentration and salivary 
alpha amylase among   patients were variable. This fin-
ding might be due to countless factors, such as age, sex, 
diet, stress, medication or habits.
Changes in stimulated saliva composition over basal sa-
liva were detected. Such modifications would not neces-
sarily depend on drug action but rather on the increase 
in salivary flow since no significant differences in either 
the concentration of organic or in the inorganic stimula-
ted saliva were found at different times of therapy.
Current results let us suggest the finding of pathogenic 
bacteria increase would enhance the risk of periodontal 
disease as evidenced by the depth of the vestibular sul-
cus; the single oral health index that did not revert after 
treatment.  This result is particularly relevant since it 
will draw patients’ awareness to the need of developing 
therapeutical care at the very start of therapy, thus pre-
venting complications that jeopardize the health of the 
stomatognathic system during oncologic management 
(25,26).
Although some results are in agreement with scientific 
reviews, we cannot ignore contradictory reports due to 
the different types of cancer and consequently varied 
therapeutical protocols, lack of standardized methods 
and relatively short follow-up lapses which limit the 
possibility of gathering consistent results (27,28).
Including dental dentistry specialists in the interdisci-
plinary oncologic team will aid cancer treatment. 
The prevention and screening of oral disorders detect-
ed during cytostatic treatment will potentially prevent 
those side effects which may negatively affect the pa-
tients’ quality of life. 
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